News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

May 19, 2005
If you are in the United States and are accessing this web page in response to a US advertisement funded by Common Sense for Drug Policy, please note that this advertisement is not endorsed by GW Pharmaceuticals.
May 11, 2005
GW and Bayer Healthcare AG announce certain amendments to their marketing agreement for Sativex in the UK and Canada.
Apr 19, 2005
GW announces that Sativex® has been granted regulatory approval in Canada for the symptomatic relief of neuropathic pain in multiple sclerosis.
Mar 31, 2005
GW Pharmaceuticals plc, the company which develops and manufactures a range of new medicines based on cannabis and other controlled drugs, announces its interim results for the six months ended 31 March 2005.
Mar 23, 2005
GW is pleased to announce the promotion of Dr Stephen Wright to GW’s Board of Directors with immediate effect.
Feb 28, 2005
US Founder Investors increase stake with approx $5m additional investment
Jan 19, 2005
GW Pharmaceuticals announces its Preliminary Results for the year ended 30 September 2004
Jan 19, 2005
GW Pharmaceuticals announces positive preliminary results in a Phase III clinical trial with Sativex® in 177 patients with severe cancer pain.

Pages